← Back to home

UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Clinical trials for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New hope for advanced stomach cancer: pfizer tests promising drug combo

Disease control Not yet recruiting

This study is testing whether a new drug called PF-08634404 works better when combined with standard chemotherapy for people with advanced stomach, esophageal, or gastroesophageal cancers. The trial has two parts: first checking safety and early effectiveness, then directly compa…

Matched conditions: UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Get alerted when new UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA trials appear

New hope for advanced stomach cancer: pfizer tests promising drug combo